Dr. Thomas Ebert, M.D

NPI: 1336278225
Total Payments
$9,270
2022 Payments
$1,298
Companies
7
Transactions
15

Payment Breakdown by Category

Consulting$7,500 (80.9%)
Food & Beverage$1,407 (15.2%)
Travel$362.34 (3.9%)
Other$0.00 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $7,500 4 80.9%
Food and Beverage $1,407 9 15.2%
Travel and Lodging $362.34 2 3.9%

Top Paying Companies

Company Total Records Latest Year
Celgene Corporation $7,262 5 $0 (2019)
McKesson Corporation $1,200 2 $0 (2022)
Amgen Inc. $348.94 3 $0 (2019)
Janssen Biotech, Inc. $167.35 2 $0 (2022)
Merck Sharp & Dohme Corporation $111.29 1 $0 (2019)
GlaxoSmithKline, LLC. $92.93 1 $0 (2018)
PFIZER INC. $86.93 1 $0 (2017)

Payment History by Year

Year Amount Transactions Top Company
2022 $1,298 3 McKesson Corporation ($1,200)
2021 $69.74 1 Janssen Biotech, Inc. ($69.74)
2019 $3,836 3 Celgene Corporation ($3,600)
2018 $3,859 6 Celgene Corporation ($3,662)
2017 $206.71 2 Amgen Inc. ($119.78)

All Payment Transactions

15 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
11/01/2022 Janssen Biotech, Inc. ERLEADA (Drug) Food and Beverage In-kind items and services $97.61 General
Category: Oncology
04/12/2022 McKesson Corporation Consulting Fee Cash or cash equivalent $610.00 General
03/18/2022 McKesson Corporation Consulting Fee Cash or cash equivalent $590.00 General
11/02/2021 Janssen Biotech, Inc. ERLEADA (Drug) Food and Beverage In-kind items and services $69.74 General
Category: Oncology
12/12/2019 Merck Sharp & Dohme Corporation BRIDION (Drug) Food and Beverage In-kind items and services $111.29 General
Category: NEUROSCIENCE
02/19/2019 Amgen Inc. XGEVA (Biological) Food and Beverage In-kind items and services $125.00 General
Category: Oncology
01/31/2019 Celgene Corporation JCAR017 (Drug) Consulting Fee Cash or cash equivalent $3,600.00 General
05/24/2018 Celgene Corporation Travel and Lodging Cash or cash equivalent $100.25 General
05/16/2018 Celgene Corporation Consulting Fee Cash or cash equivalent $2,700.00 General
05/16/2018 Celgene Corporation Food and Beverage Cash or cash equivalent $600.00 General
05/11/2018 Celgene Corporation Travel and Lodging Cash or cash equivalent $262.09 General
03/26/2018 GlaxoSmithKline, LLC. NUCALA (Biological) Food and Beverage In-kind items and services $92.93 General
Category: RESPIRATORY
02/08/2018 Amgen Inc. Neulasta (Biological) Food and Beverage In-kind items and services $104.16 General
Category: Oncology
02/28/2017 Amgen Inc. Food and Beverage In-kind items and services $119.78 General
02/15/2017 PFIZER INC. IBRANCE (Drug) Food and Beverage In-kind items and services $86.93 General
Category: ONCOLOGY

About Dr. Thomas Ebert, M.D

Dr. Thomas Ebert, M.D is a Nephrology healthcare provider based in Springfield, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/05/2007. The National Provider Identifier (NPI) number assigned to this provider is 1336278225.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Ebert, M.D has received a total of $9,270 in payments from pharmaceutical and medical device companies, with $1,298 received in 2022. These payments were reported across 15 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($7,500).

Practice Information

  • Specialty Nephrology
  • Location Springfield, MA
  • Active Since 03/05/2007
  • Last Updated 07/08/2007
  • Taxonomy Code 207RN0300X
  • Entity Type Individual
  • NPI Number 1336278225

Products in Payments

  • JCAR017 (Drug) $3,600
  • ERLEADA (Drug) $167.35
  • XGEVA (Biological) $125.00
  • BRIDION (Drug) $111.29
  • Neulasta (Biological) $104.16
  • NUCALA (Biological) $92.93
  • IBRANCE (Drug) $86.93

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Nephrology Doctors in Springfield